Analysts Set Expectations for UNCY FY2030 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright issued their FY2030 earnings per share estimates for Unicycive Therapeutics in a research report issued on Monday, January 26th. HC Wainwright analyst S. Ramakanth expects that the company will earn $9.77 per share for the year. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

UNCY has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 2nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Unicycive Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

Unicycive Therapeutics Stock Down 0.6%

Shares of Unicycive Therapeutics stock opened at $6.88 on Tuesday. The company’s 50-day simple moving average is $6.06 and its 200-day simple moving average is $5.03. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The firm has a market cap of $147.85 million, a price-to-earnings ratio of -1.74 and a beta of 1.85.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.20.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of large investors have recently made changes to their positions in the company. Vivo Capital LLC increased its stake in shares of Unicycive Therapeutics by 57.4% in the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after purchasing an additional 652,901 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Unicycive Therapeutics in the third quarter valued at approximately $512,000. Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics in the third quarter worth $182,000. Vanguard Group Inc. increased its position in Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after acquiring an additional 52,925 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics during the 2nd quarter valued at $55,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.